Information about pipeline products


A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
Lee JH, Chen TWW, Hsu CH, et al.
Invest New Drugs. 2020;38(1):99-110.
Breast Cancer
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
Varghese D, Cruz GI, Johanson C, et al.
Int J Clin Oncol. 2024; 29:780-789.
Breast Cancer
A retrospective study of do-not-do practice recommendations in metastatic breast cancer in Spain
Vega IG-C, Rescalvo MAG, Moreno F, et al.
Revista de Senología y Patología Mamaria 2024;37
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
Izutsu K, Makita S, Nosaka K, et al.
Blood. 2023;141(10):1159-1168.
Breast Cancer
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
Garrido C, Manoogian M, Ghambire D, et al.
Virchows Arch. 2023. doi: 10.1007/s00428-023-03671-x. Online ahead of print.
Breast Cancer
Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib study
Modi S, Park H, Murthy RK, et al.
J Clin Oncol. 2020;38(17):1887-1896.
Lung Cancer Other/Multi-Tumor
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development
Lu Y, Liang S, Hong Y, et al.
CPT Pharmacometrics Syst Pharmacol. 2024;13(1):23-28.
Lung Cancer
Augmenting external control arms using Bayesian borrowing: A case study in first-line non-small cell lung cancer
Struebing A, McKibbon C, Ruan H, et al.
J Comp Eff Res. 2024 May;13(5):e230175.
Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Kojima Y, Sudo K, Yoshida H, et al.
Kojima et al. Cancer Cell International (2023) 23:18
Lung Cancer
Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
Baba T, Kusumoto M, Kato T, et al.
Baba et al. Int J Clin Oncol. 2023 Dec;28(12):1585-1596. doi: 10.1007/s10147-023-02414-x. Epub 2023 Oct 3.
Páginas: 1  2  3  4  5  6  7  8  9  10  11